---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009366"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T20:53:47.644318+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical Q1 2022 net loss $7.6M; CLS-AX cohort 4 enrolling

## Summary
- Net loss of $7.6M ($0.13 per share) vs $7.4M ($0.13) in Q1 2021; revenue $347K vs $34K.
- Cash and equivalents $34.4M; company expects sufficient for at least next 12 months.
- XIPERE (suprachoroidal triamcinolone) commercially launched in U.S. by Bausch + Lomb for uveitic macular edema.
- CLS-AX Phase 1/2a OASIS trial: Cohort 4 enrolling at 1.0 mg; no dose-limiting toxicities in Cohort 3; safety data expected Q4 2022.
- Benjamin R. Yerxa appointed to Board of Directors.

## SEC filing metadata
- accession: 0000950170-22-009366
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017022009366/0000950170-22-009366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017022009366/clsd-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009366
- JSON: https://secwatch.observer/filing/0000950170-22-009366.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.